NousCom presents at EMBL-Cancer Core Europe Conference: Cancer Immunotherapy - Nouscom

NousCom presents at EMBL-Cancer Core Europe Conference: Cancer Immunotherapy

By fabiocrognale

Posted 02/02/2017

In External Presentations

EMBL Heidelberg, Germany

Abstract Title: Personalized cancer vaccine based on ChAd vaccine improves over the anti-PD1 activity.

Recent Posts

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023
Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy
NOUSCOM ANNOUNCES THE PROMOTIONS OF LOREDANA SIANI TO VICE PRESIDENT OF TECHNICAL AND CMC DEVELOPMENT, TIFFANY BROOKE MULLER TO SENIOR VICE PRESIDENT OF FINANCE AND MORENA D’ALISE TO VICE PRESIDENT OF IMMUNOLOGY
Nouscom announces appointment of Sarah Runswick as Senior Director of Clinical Science

error: Content is protected !!!